3c4f: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:3c4f.jpg|left|200px]]
[[Image:3c4f.jpg|left|200px]]


{{Structure
<!--
|PDB= 3c4f |SIZE=350|CAPTION= <scene name='initialview01'>3c4f</scene>, resolution 2.07&Aring;
The line below this paragraph, containing "STRUCTURE_3c4f", creates the "Structure Box" on the page.
|SITE= <scene name='pdbsite=AC1:C4f+Binding+Site+For+Residue+A+1'>AC1</scene> and <scene name='pdbsite=AC2:C4f+Binding+Site+For+Residue+B+2'>AC2</scene>
You may change the PDB parameter (which sets the PDB file loaded into the applet)
|LIGAND= <scene name='pdbligand=C4F:3-(3-METHOXYBENZYL)-1H-PYRROLO[2,3-B]PYRIDINE'>C4F</scene>
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
|ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span>
or leave the SCENE parameter empty for the default display.
|GENE= FGFR1, FGFBR, FLG, FLT2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])
-->
|DOMAIN=
{{STRUCTURE_3c4f| PDB=3c4f  | SCENE= }}  
|RELATEDENTRY=[[3c4c|3C4C]], [[3c4d|3C4D]], [[3c4e|3C4E]]
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3c4f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3c4f OCA], [http://www.ebi.ac.uk/pdbsum/3c4f PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=3c4f RCSB]</span>
}}


'''FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole'''
'''FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole'''
Line 28: Line 25:
[[Category: Wang, W.]]
[[Category: Wang, W.]]
[[Category: Zhang, K Y.J.]]
[[Category: Zhang, K Y.J.]]
[[Category: alternative splicing]]
[[Category: Alternative splicing]]
[[Category: atp-binding]]
[[Category: Atp-binding]]
[[Category: chromosomal rearrangement]]
[[Category: Chromosomal rearrangement]]
[[Category: disease mutation]]
[[Category: Disease mutation]]
[[Category: dwarfism]]
[[Category: Dwarfism]]
[[Category: fgfr]]
[[Category: Fgfr]]
[[Category: fgfr1]]
[[Category: Fgfr1]]
[[Category: fibroblast growth factor receptor]]
[[Category: Fibroblast growth factor receptor]]
[[Category: glycoprotein]]
[[Category: Glycoprotein]]
[[Category: heparin-binding]]
[[Category: Heparin-binding]]
[[Category: immunoglobulin domain]]
[[Category: Immunoglobulin domain]]
[[Category: kallmann syndrome]]
[[Category: Kallmann syndrome]]
[[Category: membrane]]
[[Category: Membrane]]
[[Category: nucleotide-binding]]
[[Category: Nucleotide-binding]]
[[Category: phosphoprotein]]
[[Category: Phosphoprotein]]
[[Category: polymorphism]]
[[Category: Polymorphism]]
[[Category: receptor tyrosine kinase]]
[[Category: Receptor tyrosine kinase]]
[[Category: transferase]]
[[Category: Transferase]]
[[Category: transmembrane]]
[[Category: Transmembrane]]
[[Category: tyrosine kinase domain]]
[[Category: Tyrosine kinase domain]]
[[Category: tyrosine-protein kinase]]
[[Category: Tyrosine-protein kinase]]
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 21:20:18 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 05:30:32 2008''

Revision as of 21:20, 4 May 2008

File:3c4f.jpg

Template:STRUCTURE 3c4f

FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole


OverviewOverview

BRAF(V600E) is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer. Therefore, we pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular. By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered. PLX4720, a 7-azaindole derivative that inhibits B-Raf(V600E) with an IC(50) of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochemical and cellular assays. PLX4720 preferentially inhibits the active B-Raf(V600E) kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele. Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-Raf(V600E)-bearing tumor cell lines but not in cells lacking oncogenic B-Raf. In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-Raf(V600E)-positive cells. In B-Raf(V600E)-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity. The work described here represents the entire discovery process, from initial identification through structural and biological studies in animal models to a promising therapeutic for testing in cancer patients bearing B-Raf(V600E)-driven tumors.

About this StructureAbout this Structure

3C4F is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity., Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G, Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. Epub 2008 Feb 19. PMID:18287029 Page seeded by OCA on Sun May 4 21:20:18 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA